BrainStorm Cell Therapeutics Inc. shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a...
BrainStorm Cell Therapeutics Inc.
shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednesday gave a thumbs-down to the company’s investigational treatment for amyotrophic lateral sclerosis . The FDA advisors voted that the treatment, the mesenchymal stem cell therapy NurOwn, did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA Panel Rejects Brainstorm Cell Therapeutics ALS TreatmentBy Liz Essley Whyte A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic...
Weiterlesen »
Binance's market share among non-USD exchanges slips to 50%Binance has lost considerable market share among global rivals that do not offer U.S. dollar support this year.
Weiterlesen »
More than 50% Of People Have This Genetic Variant — How To Eat For ItAnd what supplements you should definitely prioritize.
Weiterlesen »
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trialPliant Therapeutics Inc. shares gained 23% premarket on Tuesday after the company released results from a trial of bexotegrast, a treatment for a chronic...
Weiterlesen »
Niles: After 50 years, Knott’s still leads the industry with Scary FarmThe Halloween event, which has been imitated around the globe, shows what theme parks are capable of achieving without spending huge sums.
Weiterlesen »
Nancy Mace: 'I Give It a 50-50 Shot on Whether or Not We Have a Government Shutdown'Monday, during an appearance on FBN's 'Cavuto: Coast to Coast,' Rep. Nancy Mace (R-SC) weighed in on the possibility of a federal government shutdown. | Clips
Weiterlesen »